305 related articles for article (PubMed ID: 21108586)
1. Rifaximin for the treatment of hepatic encephalopathy.
Mullen K; Prakash R
Expert Rev Gastroenterol Hepatol; 2010 Dec; 4(6):665-77. PubMed ID: 21108586
[TBL] [Abstract][Full Text] [Related]
2. Durability of rifaximin response in hepatic encephalopathy.
Neff GW; Jones M; Broda T; Jonas M; Ravi R; Novick D; Kaiser TE; Kemmer N
J Clin Gastroenterol; 2012 Feb; 46(2):168-71. PubMed ID: 22011586
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of rifaximin versus lactulose for reducing the recurrence of overt hepatic encephalopathy and hopitalizations in cirrhosis.
Irimia R; Trifan A
Rev Med Chir Soc Med Nat Iasi; 2012; 116(4):1021-7. PubMed ID: 23700882
[TBL] [Abstract][Full Text] [Related]
4. Randomised clinical trial: rifaximin improves health-related quality of life in cirrhotic patients with hepatic encephalopathy - a double-blind placebo-controlled study.
Sanyal A; Younossi ZM; Bass NM; Mullen KD; Poordad F; Brown RS; Vemuru RP; Mazen Jamal M; Huang S; Merchant K; Bortey E; Forbes WP
Aliment Pharmacol Ther; 2011 Oct; 34(8):853-61. PubMed ID: 21848797
[TBL] [Abstract][Full Text] [Related]
5. Rifaximin for treatment of hepatic encephalopathy.
Maclayton DO; Eaton-Maxwell A
Ann Pharmacother; 2009 Jan; 43(1):77-84. PubMed ID: 19092143
[TBL] [Abstract][Full Text] [Related]
6. A randomized, double-blind, controlled trial comparing rifaximin plus lactulose with lactulose alone in treatment of overt hepatic encephalopathy.
Sharma BC; Sharma P; Lunia MK; Srivastava S; Goyal R; Sarin SK
Am J Gastroenterol; 2013 Sep; 108(9):1458-63. PubMed ID: 23877348
[TBL] [Abstract][Full Text] [Related]
7. Update on management of patients with overt hepatic encephalopathy.
Chacko KR; Sigal SH
Hosp Pract (1995); 2013 Aug; 41(3):48-59. PubMed ID: 23948621
[TBL] [Abstract][Full Text] [Related]
8. RiMINI - the influence of rifaximin on minimal hepatic encephalopathy (MHE) and on the intestinal microbiome in patients with liver cirrhosis: study protocol for a randomized controlled trial.
Schulz C; Schütte K; Kropf S; Schmitt FC; Vasapolli R; Kliegis LM; Riegger A; Malfertheiner P
Trials; 2016 Feb; 17(1):111. PubMed ID: 26926775
[TBL] [Abstract][Full Text] [Related]
9. Rifaximin is safe and well tolerated for long-term maintenance of remission from overt hepatic encephalopathy.
Mullen KD; Sanyal AJ; Bass NM; Poordad FF; Sheikh MY; Frederick RT; Bortey E; Forbes WP
Clin Gastroenterol Hepatol; 2014 Aug; 12(8):1390-7.e2. PubMed ID: 24365449
[TBL] [Abstract][Full Text] [Related]
10. Optimal treatment of hepatic encephalopathy.
Waghray A; Waghray N; Kanna S; Mullen K
Minerva Gastroenterol Dietol; 2014 Mar; 60(1):55-70. PubMed ID: 24632768
[TBL] [Abstract][Full Text] [Related]
11. Evolving concepts: the negative effect of minimal hepatic encephalopathy and role for prophylaxis in patients with cirrhosis.
Prakash RK; Kanna S; Mullen KD
Clin Ther; 2013 Sep; 35(9):1458-73. PubMed ID: 23972578
[TBL] [Abstract][Full Text] [Related]
12. Management of hepatic encephalopathy in the hospital.
Leise MD; Poterucha JJ; Kamath PS; Kim WR
Mayo Clin Proc; 2014 Feb; 89(2):241-53. PubMed ID: 24411831
[TBL] [Abstract][Full Text] [Related]
13. Rifaximin versus nonabsorbable disaccharides in the management of hepatic encephalopathy: a meta-analysis.
Jiang Q; Jiang XH; Zheng MH; Jiang LM; Chen YP; Wang L
Eur J Gastroenterol Hepatol; 2008 Nov; 20(11):1064-70. PubMed ID: 19047837
[TBL] [Abstract][Full Text] [Related]
14. Prolonged remission from hepatic encephalopathy with rifaximin: results of a placebo crossover analysis.
Bajaj JS; Barrett AC; Bortey E; Paterson C; Forbes WP
Aliment Pharmacol Ther; 2015 Jan; 41(1):39-45. PubMed ID: 25339518
[TBL] [Abstract][Full Text] [Related]
15. Rifaximin: new therapeutic indication and future directions.
Rivkin A; Gim S
Clin Ther; 2011 Jul; 33(7):812-27. PubMed ID: 21741091
[TBL] [Abstract][Full Text] [Related]
16. Comparison of Rifaximin Plus Lactulose with the Lactulose Alone for the Treatment of Hepatic Encephalopathy.
Ahire K; Sonawale A
J Assoc Physicians India; 2017 Aug; 65(8):42-46. PubMed ID: 28799305
[TBL] [Abstract][Full Text] [Related]
17. The cost-effectiveness and budget impact of competing therapies in hepatic encephalopathy - a decision analysis.
Huang E; Esrailian E; Spiegel BM
Aliment Pharmacol Ther; 2007 Oct; 26(8):1147-61. PubMed ID: 17894657
[TBL] [Abstract][Full Text] [Related]
18. [Intestine specific broad spectrum antibiotic. Rifaximin: therapy option in hepatic encephalopathy].
MMW Fortschr Med; 2014 Feb; 156(3):64-5. PubMed ID: 24938070
[No Abstract] [Full Text] [Related]
19. Treatment options for hepatic encephalopathy.
Schiano TD
Pharmacotherapy; 2010 May; 30(5 Pt 2):16S-21S. PubMed ID: 20412036
[TBL] [Abstract][Full Text] [Related]
20. Rifaximin is largely safe and well tolerated but caution is necessary when taken with statins.
Cacciottolo TM; Kingdon A; Alexander GJ
Clin Gastroenterol Hepatol; 2014 Oct; 12(10):1765. PubMed ID: 24703862
[No Abstract] [Full Text] [Related]
[Next] [New Search]
